Adverse effects of antiretroviral therapy: Focus on orofacial effects

Expert Opinion on Drug Safety

Volumn 1, Issue 4, 2002, Pages 307-317

  Dios, Pedro Diz ^a   Scully, Crispian ^b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

adverse effects; antiretroviral; HIV; oral

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXPERT WITNESS; GROWTH, DEVELOPMENT AND AGING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOUTH DISEASE; REVIEW;

ANTI-HIV AGENTS; EXPERT TESTIMONY; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOUTH DISEASES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0043237817     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.1.4.307     Document Type: Review

References (85)

1. NO AUTHORS LISTED: Pneumocystis pneumonia-Los Angeles. MMWR Morb. Mortal. Wkly Rep. (1981) 30:250-252.
2. GOTTLIEB NE, GOTTLIEB MS, SCHROFF R et al.: Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. (1981) 305:1425-1431. (Pubitemid 12240076)
3. BARRE-SINOUSSI F, CHERMANN JC, REY F et al.: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 220:868-871. (Pubitemid 13080157)
4. TEMIN H: Origin and general nature of retrovirus. In: The Retroviridae ( Vol. 1). Levey JA (Ed.), Plenun Press, New York, London (1992):1-18.
5. POPOVIC M, SARNGADHARAN MG, READ E, GALLO RC: Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 224:497-500. (Pubitemid 14134740)
6. CLAVEL F, BRUN-VEZINET F, GUETARD D et al.: LAV Type II: a second retrovirus associated with AIDS in West Africa. C. R. Acad. Sci. III (1986) 302:485-488. (Pubitemid 16074582)
7. PRINGLE CR: The universal system of virus taxonomy of the International Committee on Virus Taxonomy (ICTV), including new proposals ratified since publication of the Sixth ICTV Report in 1995. Arch. Virol. (1998) 143:203-210. (Pubitemid 128713001)
8. GAO F, BAILES E, ROBERTSON DL et al.: Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature (1999) 397:436-441.
9. PLOTKIN SA: CHAT oral polio vaccine was not the source of human immunodeficiency virus Type 1 group M for humans. Clin. Infect. Dis. (2001) 32:1068-1084. (Pubitemid 32303192)
10. HO DD: Viral counts count in HIV infection. Science (1996) 272:1124-1125.
11. FENG Y, BRODER CC, KENNEDY PE, BERGER EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 272:872-877. (Pubitemid 26154590)
12. DRAGIC T, LITWIN V, ALLAWAY GP et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 381:667-673. (Pubitemid 26197680)
13. ZHANG L, HE T, HUANG Y et al.: Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus Type 1. J. Virol. (1998) 72:9307-9312. (Pubitemid 28471879)
14. SPINA CA, KWOH TJ, CHOWERS MY, GUATELLI JC, RICHMAN DD: The importance of nef in the induction of human immunodeficiency virus Type 1 replication from primary quiescent CD4 lymphocytes. J. Exp. Med. (1994) 179:115-123. (Pubitemid 24012976)
15. ZACK JA, ARRIGO SJ, WEITSMAN SR, GO AS, HAISLIP A, CHEN IS: HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 61:213-222.
16. KATZENSTEIN D: Combination therapies for HIV infection and genomic drug resistance. Lancet (1997) 350:970.
17. NO AUTHORS LISTED: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J Kaiser Family Foundation. Morb. Mortal. Wkly. Rep. (1998) 47(RR-5):43-82.
18. Published erratum appears in MMWR Morb. Mortal. Wkly Rep. (1998) 47(29):619.
19. BONFANTI P, CAPETTI A, RIZZARDINI G: HIV disease treatment in the era of HAART. Biomed. Pharmacother. (1999) 53:93-105. (Pubitemid 29356461)
20. VOLBERDING PA, LAGAKOS SW, KOCH MA et al.: Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N. Engl. J. Med. (1990) 322:941-949. (Pubitemid 20146627)
21. HENRY K, ERICE A, TIERNEY C et al.: A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1998) 19:339-349.
22. SHEARER GM, CLERICI M: Early T-helper cell defects in HIV infection. AIDS (1991) 5:245-253. Editorial.
23. DOLAN MJ, CLERICI M, BLATT SP et al.: In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J. Infect. Dis. (1995) 172:79-87.
24. MOORE RD: Decline in CMV and other opportunistic disease with combination antiretroviral therapy. Proceedings of the 8th International Conference on Retrovirus and Opportunistic Infections. Chicago, USA (1998).
25. POWDERLY WG, LANDAY A, LEDERMAN MM: Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA (1998) 280:72-77. (Pubitemid 28415000)
26. TEMESGEN Z, WRIGHT AJ: Antiretrovirals. Mayo Clin. Proc. (1999) 74:1284-1301.
27. CARR A, COOPER DA: Adverse effects of antiretroviral therapy. Lancet (2000) 356:1423-1430.
28. EYESON JD, WARNAKULASURIYA KAAS, JOHNSON NW: Prevalence and incidence of oral lesions-the changing scene. Oral Dis. (2000) 6:267-273.
29. DIOS PD, OCAMPO A, MIRALLES C, LIMERES J, TOMAS I: Changing prevalence of human immunodeficiency virus-associated oral lesions. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (2000) 90:403-404.
30. FISCHL MA, RICHMAN DD, GRIECO MH et al.: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. (1987) 317:185-191. (Pubitemid 17114872)
31. KINLOCH-DE LOES S, HIRSCHEL BJ, HOEAN B et al.: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N. Engl. J. Med. (1995) 333:408-413.
32. LARDER BA, DARBY G, RICHMAN DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 243:1731-1734. (Pubitemid 19106971)
33. FICARRA G, FLAITZ CM, GAGLIOTI D et al.: White lichenoid lesions of the buccal mucosa in patients with HIV infection. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (1993) 76:460-466. (Pubitemid 23318930)
34. VALENCIA ME, LOPEZ DUPLA JM, LAVILLA P, GIL AGUADO A: [Hyperpigmentation and zidovudine]. Med. Clin. (Barc.) (1989) 92:357-358. Spanish.
35. GREENGERG RG, GERGER TG: Nail and mucocutaneous hyperpigmentation with azidothymidine therapy. J. Am. Acad. Dermatol. (1990) 22:327-330.
36. POIZOT-MARTIN I, LEFEUILLADE A, DHIVER C et al: Cutaneo-mucosal hyperpigmentation in AIDS. Four cases. Presse Med. (1991) 20:632-636.
37. AHFS DRUG INFORMATION MONOGRAPH: Zidovudine. Am. Soc. Hosp. Pharm. (1990):386.
38. SCHWANDER S, KERN P: Tongue ulcer in azidothymidine-induced neutropenia. Rapid increase in neutrophils and healing of the ulcer by substitution of recombinant human granulocyte colony stimulating factor (rhG-CSF). Med. Klin. (1993) 88:60-62. (Pubitemid 23109244)
39. KHAN J, LAGAKOS S, RICHMAN D et al: A controlled trial comparing continued zidovudine with didanosine in HIV infection. N. Engl. J. Med. (1992) 327:581-587.
40. SQUIRES K: The Atlantic study: a randomized, open-labeled trial comparing two protease inhibitor sparing antiretroviral strategies versus a standard protease containing regimen, final 48 week data. Proceedings of the 13th International AIDS Conference. Durban, South Africa (2000).
41. SCHRADER S, SHARMA S, SEEKINS D et al: Comparison of HIV RNA suppression produced by triple regimens containing either didanosine enteric-coated or didanosine tablet formulations each administered once daily. Proceedings of the 8th International Conference on Retrovirus and Opportunistic. Chicago, USA (1998).
42. PARNEIX-SPAKE A, BASTUJI-GARIN S, LEVY Y, DUBREUIL-LEMAIRE ML, ROUJEAU JC: Didanosine as probable cause of Stevens-Johnson syndrome. Lancet (1992) 340:857-858.
43. DODD CL, GREENSPAN D, WESTENHOUSE JL, KATZ MH: Xerostomia associated didanosine. Lancet (1992) 340:790.
44. ALLAN JD, CONNOLLY KJ, FITCH H et al: Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine. Clin. Infect. Dis. (1993) 16(Suppl. 1):46-51.
45. MCNEELY MC, YARCHOAN R, BRODER S, LAWLEY TJ: Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection. J. Am. Acad. Dermatol. (1989) 21:1213-1217. (Pubitemid 20216991)
46. ADKINS JC, PETERS DH, FAULDS D: Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs (1997) 53:1054-1080. (Pubitemid 27254577)
47. CARR A, SAMARAS K, BURTON S et al.: A syndrome of peripheral lipodystrophy, hiperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12:51-58.
48. MALLAL S, JOHN M, MOORE C et al: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fast wasting in patients with HIV infection. AIDS (2000) 14:1309-1316. (Pubitemid 30459502)
49. CHENE G, ANGELINI E, COTTE L et al: Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin. Infect. Dis. (2002) 34:649-57. (Pubitemid 34165328)
50. HADIGAN C, BORGONHA S, RABE J, YOUNG V, GRINSPOON S: Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism (2002) 51:1143-1147.
51. PLUDA J, COOLEY T, MONTANER J et al: A Phase I/II study of 2 ,3-dideoxy-3-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. (1995) 171:1438-1447.
52. HEATH K, HOGG R, CHAN K et al: Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS (2001) 15:231-239. (Pubitemid 32142299)
53. SCULLY C, DIZ DIOS P: HIV topic update: orofacial effects of antiretroviral therapies. Oral Dis. (2001) 7:205-210. (Pubitemid 32734917)
54. MARTIN-CARBONERO L, BARREIRO P, SORIANO V et al: Tolerability of abacavir in the clinical setting. Clin. Microbiol. Infect. (2000) 6:621-622. (Pubitemid 34966081)
55. GILDEN D: Tenofovir: Gilead applies for approval; expanded access liberalized. AIDS Treat. News (2001) 11:2-3.
56. ALBENGES E, LE LOUET H, TILLEMENT J: Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf (1998) 18:83-97. (Pubitemid 28080742)
57. BARREIRO P, SORIANOV, CASAS E et al.: Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS (2000) 14:2153-2157.
58. WETTERWALD E, LE CLEACH L, MICHEL C, DAVID E, REVUZ J: Nevirapine-induced overlap Stevens-Johnson syndrome/toxic epidermal necrolysis. Br. J. Dermatol. (1999) 140:980-982. (Pubitemid 29238491)
59. PARA M, MEECHANP, HOLDEN-WILTSE J et al.: ACTG 260: a randomized, Phase I-II dose ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. Antimicrob Agents Chemother. (1999) 43:1373-1378. (Pubitemid 29259328)
60. STASZEWSKI S, MORALES-RAMIREZ J, TASHIMA KT et al: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine in the treatment of HIV-1 infections in adults. N. Engl. J. Med. (1999) 341:1865-1873.
61. MIRO J, ANTELA A, ARRIZABALAGA J et al: [Recommendations of GESIDA (Grupo de Estudio de SIDA)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (II)] Enferm. Infecc. Microbiol. Clin. (2000) 18:396-412. Spanish.
62. KOHL NE, EMINI EA, SCHLEIF WA et al.: Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA (1988) 85:4686-4690.
63. CAMERON DW, JAPOUR AJ, XU Y et al: Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS (1999) 13:213-224. (Pubitemid 29050409)
64. OLIVE A, SALAVERT A, MANRIQUEZ M, CLOTET B, MORAGAS A: Parotid lipomatosis in HIV positive patients: a new clinical disorder associated with protease inhibitors. Ann. Rheum. Dis. (1998) 57:749. (Pubitemid 29009691)
65. PORTER SR, SCULLY C: HIV topic update: protease inhibitor therapy and oral health care. Oral. Dis. (1998) 4:159-163. (Pubitemid 28427798)
66. MARKOWITZ M, SAAG M, POWDERLY W et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. (1995) 333:1534-1539.
67. CAMERON DW, HEATH-CHIOZZI M, DANNER S et al: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet (1998) 351:543-549. (Pubitemid 28077559)
68. MAX B, SHERER R: Management of the adverse effects of antiretroviral therapy and medication adherence. Clin. Infect. Dis. (2000) 30: S96-S116. (Pubitemid 32268977)
69. PLOSKER G, NOBLES: Indinavir. A review of its use in the management of HIV infection. Drugs (1999) 58:1165-1203. (Pubitemid 30055050)
70. FOX PA, HOWKINS DA, STAUGHTON RC: Cheilitis in association with indinavir. Sex. Transm. Infect. (2000) 76:323-324.
71. CASARIEGO Z, POMBO T, PEREZ H, PATTERSON P: Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy. Presentation of six clinical cases. Med. Oral (2001) 6:19-30. (Pubitemid 32162683)
72. SCHIFFMAN SS, ZERVAKIS J, HEFFRON S, HEALD AE: Effect of protease inhibitors on the sense of taste. Nutrition (1999) 15:767-772. (Pubitemid 29461023)
73. SAAG M, TEBAS P, SENSION M et al: Randomized, doble-blind comparison of two nelfinavir dosis plus nucleosides in HIV-infected patients (Agouron study 511). AIDS (2001) 15:1971-1978. (Pubitemid 32980639)
74. GOODGAME JC, POTTAGE JC Jr, JABLONOWSKI H et al.: Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team. Antivir. Ther. (2000) 5:215-225.
75. KUMAR GN, DYKSTRA J, ROBERTS EM et al.: Potent inhibition of the cytochrome P450 3A mediated human microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interation. Drug Metab. Dispos. (1999) 27:902-908. (Pubitemid 29347590)
76. MURPHY R, BRUN S, HICKS C et al.: ABT.378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-week results. AIDS (2001) 15:1-9.
77. MURRI R, AMMASSARI A, GALLICANO K et al.: Patient-reported nonadherence to HAART is related to protease inhibitor levels. J. Acquir. Immune Defic. Syndr. (2000) 24:123-128. (Pubitemid 30640957)
78. PATTON LL, MCKAIG R, STRAUSS R et al.: Changing prevalence of oral manifestations of human deficiency virus in the 3era of protease inhibitor therapy. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (2000) 89:299-304.
79. SCHMIDT-WESTHAUSEN AM, PRIEPKE F, BERGMANN FJ et al.: Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J. Oral Pathol. Med. (2000) 29:336-341. (Pubitemid 30459306)
80. CAPACCIO P, MONFORTE A, MORONI M, OTTAVIANI F: Salivary stone lithotripsy in the HIV patient. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (2002) 93:525-527. (Pubitemid 41124640)
81. GEA-BANACLOCHEJ, LANE H: Immune reconstitution in HIV infection. AIDS (1999) 12:S25-S38.
82. FRENCH M: Antiretroviral therapy: immune restoration disease in HIV-infected patients on HAART. AIDS (1999) 8:548-562.
83. GREENSPAN D, CANCHOLA AJ, MACPHAIL LA, CHEIKH B, GREENSPAN JS: Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet (2001) 357:1411-1412. (Pubitemid 32455371)
84. KING MD, REZNIK DA, O'DANIELS CM, LARSEN NM, OSTERHOLT D, BLUMBERGT HM: Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin. Infect. Dis. (2002) 34:641-648. (Pubitemid 34165327)
85. WEIR A, WANSBROUGH-JONES M: Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS (1997) 11:1895-1896. (Pubitemid 27500974)